Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Beth Schrope

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0313-8120; OpenAlex author ID A5075915121. Sources: ClinicalTrials.gov.

Their work

Papers
13
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 13

  1. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  2. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Co-author DOI 10.1093/oncolo/oyaf162↗
  3. Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy. Co-author DOI 10.1002/jso.27851↗
  4. Transfusion of salvaged red blood cells during pancreatic ductal adenocarcinoma operations. Co-author DOI 10.1093/bjs/znac393↗
  5. Long-term follow-up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer. Co-author DOI 10.1002/jso.27085↗
  6. Socioeconomic Predictors of Access to Care for Patients with Operatively Managed Pancreatic Cancer in New York State. Co-author DOI 10.1007/s11605-022-05320-1↗
  7. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2066767↗
  8. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elast… Co-author DOI 10.7150/thno.37965↗
  9. Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3936-1↗
  10. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-017-3556-1↗
  11. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients. Co-author DOI 10.1245/s10434-015-5034-x↗
  12. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable p… Co-author DOI 10.1002/cncr.29112↗
  13. Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer. Co-author DOI 10.1007/s00268-013-2384-z↗

Trials 1

  1. PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease Principal investigator NCT01102556↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John A. Chabot · 13 shared papers, 2014–2026 · strength 1.67
  2. Michael D. Kluger · 11 shared papers, 2016–2026 · strength 1.59
  3. Gulam Abbas Manji · 5 shared papers, 2022–2026 · strength 0.89
  4. Kazuki N. Sugahara · 4 shared papers, 2022–2025 · strength 0.78
  5. Alexander S. Thomas · 4 shared papers, 2022–2024 · strength 0.71
  6. Wooil Kwon · 4 shared papers, 2022–2024 · strength 0.71
  7. Susan Elaine Bates · 4 shared papers, 2022–2026 · strength 0.68
  8. Kenneth P. Olive · 3 shared papers, 2020–2026 · strength 0.46
  9. Paul E. Oberstein · 2 shared papers, 2020–2025 · strength 0.32
  10. Alina Cornelia Iuga · 2 shared papers, 2020–2026 · strength 0.29
  11. David Paul Horowitz · 2 shared papers, 2022 · strength 0.26
  12. Ruth Aroon White · 1 shared paper, 2025 · strength 0.22
  13. Timothy Cragin Wang · 1 shared paper, 2025 · strength 0.22
  14. Jeanine M. Genkinger · 1 shared paper, 2024 · strength 0.21
  15. M. Farzan Rashid · 2 shared papers, 2018–2019 · strength 0.20
  16. Elizabeth M. Hecht · 3 shared papers, 2015–2018 · strength 0.20
  17. Michael S. May · 1 shared paper, 2026 · strength 0.19
  18. Alexander Grenander Raufi · 1 shared paper, 2026 · strength 0.19
  19. Linda Y. Wu · 1 shared paper, 2026 · strength 0.19
  20. Li Li · 1 shared paper, 2026 · strength 0.19
  21. Benjamin Izar · 1 shared paper, 2026 · strength 0.19
  22. Tito Fojo · 1 shared paper, 2026 · strength 0.19
  23. Neha Goel · 1 shared paper, 2023 · strength 0.17
  24. Andrew D. Rhim · 1 shared paper, 2023 · strength 0.17
  25. Yvonne M. Saenger · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.